Navigation Links
BioCryst Clarifies Government Declaration Regarding Peramivir
Date:10/2/2009

BIRMINGHAM, Ala., Oct. 2 /PRNewswire-FirstCall/ -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the Office of the Secretary, Department of Health & Human Services (HHS) has issued "HHS Secretary's Declaration for the Use of the Public Readiness and Emergency Preparedness Act for the Influenza Antiviral Peramivir." Notice of this Declaration was posted today in the Federal Register and can be found on the Web at:

http://www.thefederalregister.com/d.p/2009-10-02-E9-23761

This Declaration represents a required step before an Emergency Use Authorization (EUA) may be issued. Further information regarding the EUA process may be found in a policy review available from the U.S. Centers for Disease Control (CDC) and can be found on the Web at:

http://www.cdc.gov/eid/content/13/7/1046.htm

About peramivir

Peramivir is an anti-viral agent that was discovered by BioCryst which inhibits the interactions of influenza neuraminidase, an enzyme which is critical to the spread of influenza within a host. In laboratory tests, peramivir has shown activity against pandemic H1N1 swine flu origin viral strains. Peramivir has been studied in patients with complicated and uncomplicated influenza. BioCryst's partner, Shionogi & Co., Ltd. is currently preparing to file for regulatory approval in Japan this year.

About BioCryst

BioCryst Pharmaceuticals designs, optimizes and develops novel small-molecule pharmaceuticals that block key enzymes involved in infectious diseases, cancer and inflammatory diseases. BioCryst has progressed two novel compounds into late-stage pivotal clinical trials; peramivir, an anti-viral for influenza, and forodesine, a purine nucleoside phosphorylase (PNP) inhibitor for cutaneous T-cell lymphoma (CTCL). Utilizing crystallography and structure-based drug design, BioCryst continues to discover additional compounds and to progress others through pre-clinical and early development to address the unmet medical needs of patients and physicians. The Company's strategic alliances with the U.S. Department of Health and Human Services, Shionogi & Co., Ltd., Green Cross Corporation and Mundipharma International Holdings Limited validate its scientific foundation and the utility of its product candidates. For more information, please visit the Company's Web site at www.biocryst.com.

Forward-Looking Statements

This press release contains forward-looking statements, including statements regarding future results, performance or achievements. These statements involve known and unknown risks, uncertainties and other factors which may cause our actual results, performance or achievements to be materially different from any future results, performances or achievements expressed or implied by the forward-looking statements. These statements reflect our current views with respect to future events and are based on assumptions and subject to risks and uncertainties. Given these uncertainties, you should not place undue reliance on these forward-looking statements. Some of the factors that could affect the forward-looking statements contained herein include: that peramivir may not receive emergency use authorization; that the U.S. government and ex-U.S. governments may choose not to issue a request for peramivir to treat influenza or such requests, if any, may not result in an order or such order, if any, may not be profitable for BioCryst; that to the extent peramivir is used as a treatment for H1N1 flu (or other strains of flu), there can be no assurance that it will prove effective; that HHS may further condition, reduce or eliminate future funding of the peramivir program; that ongoing peramivir clinical trials or our peramivir program in general may not be successful; that BioCryst or its licensees may not commence as expected additional human clinical trials with our product candidates; that our product candidates may not receive required regulatory clearances from the FDA; that ongoing and future pre-clinical and clinical development may not have positive results; that we or our licensees may not be able to continue future development of our current and future development programs; that our development programs and partnerships may never result in future product, license or royalty payments being received by BioCryst; that BioCryst may not be able to retain its current pharmaceutical and biotechnology partners for further development of its product candidates or it may not reach favorable agreements with potential pharmaceutical and biotechnology partners for further development of its product candidates; that our actual cash burn rate may not be consistent with our expectations; that BioCryst may not have sufficient cash to continue funding the development, manufacturing, marketing or distribution of its products and that additional funding, if necessary, may not be available at all or on terms acceptable to BioCryst. Please refer to the documents BioCryst files periodically with the Securities and Exchange Commission, specifically BioCryst's most recent Annual Report on Form 10-K, most recent Registration Statement on Form S-3 (filed November 28, 2008), Quarterly Reports on Form 10-Q, and current reports on Form 8-K, all of which identify important factors that could cause the actual results to differ materially from those contained in our projections and forward-looking statements.

BCRXW

SOURCE BioCryst Pharmaceuticals, Inc.


'/>"/>
SOURCE BioCryst Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. BioCryst Provides Update Regarding Peramivir for Influenza
2. BioCryst Pharmaceuticals Reports Positive Results of Shionogi & Co. Sponsored Phase 3 Studies of i.v. Peramivir for Influenza
3. BioCryst Provides Peramivir Update and Reports First Quarter 2009 Financial Results
4. BioCryst Pharmaceuticals to Announce Peramivir Update and First Quarter 2009 Financial Results on May 8, 2009
5. BioCryst Reports Positive Preliminary Results of a Shionogi & Co., Ltd. Sponsored Phase II Study of I.V. Peramivir for the Treatment of Influenza in the Outpatient Setting
6. BioCryst Announces Initiation of Phase II Study of Intramuscular Peramivir for the Treatment of Seasonal Influenza
7. BioCryst Updates Peramivir Clinical Development Plan
8. BioCryst Provides Forodesine HCl Update
9. BioCryst Initiates Enrollment in Pivotal Trial of Forodesine HCL in Patients with Cutaneous T-Cell Lymphoma (CTCL)
10. Mayo Clinic Clarifies Diagnosis and Treatment for Rare, Serious Blood Vessel Disease of Brain and Spinal Cord
11. Southern Research to Play Key Role in the Federal Governments Search for New Cancer Therapies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/9/2016)... -- This TforG report includes the Surgical Procedures Database ... system in South Korea . To ... provides written and numerical analysis on the current trends, ... the latest reforms of the local Healthcare system are ... The report helps businesses gain a unique insight ...
(Date:2/9/2016)... , Feb. 9, 2016  Johnson & Johnson ... Capital Markets Global Healthcare Conference on Tuesday, Feb. 23, ... Dominic Caruso , Vice President, Finance & Chief ... Consumer will represent the Company in a session scheduled ... . --> www.investor.jnj.com . --> ...
(Date:2/9/2016)... new report "Global Anti-Bacterial Drugs Market Assessment & Forecast: 2015 - ... the North America continued to lead global ... translated into revenues worth US$ 16,907.3 million. ... Asia-Pacific , Latin America , ... anti-bacterial market is inclined towards North America ...
Breaking Medicine Technology:
(Date:2/10/2016)... ... 10, 2016 , ... It’s that time of year when most people have ... Interscholastic Athletic Association of Maryland (IAAM), Hall of Fame athlete and Garrison Forest School ... aside. , That’s why one of her first decisions when her IAAM two-year presidency ...
(Date:2/9/2016)... ... February 09, 2016 , ... ... recover after a disaster, announced today the acquisition of Hawaii DKI. Hawaii DKI ... , “Investing in like-minded companies who excel at service and response helps ...
(Date:2/9/2016)... ... February 09, 2016 , ... A new study from the ... Medicare rates for a variety of medical services in Illinois as of 2015. ... 2015 Fee Schedule Rates in Illinois, are professional medical services, hospital outpatient ...
(Date:2/9/2016)... ... February 09, 2016 , ... BioPlus Specialty ... continuation of the ‘Pay It Forward’ program into 2016. BioPlus partners with several ... specialty pharmacy. , “Since our Pay It Forward program began, we are ...
(Date:2/9/2016)... (PRWEB) , ... February 10, 2016 , ... The ... the need to “level the playing field .” , As corresponding author Dr John ... we use to categorize and diagnose our chronic pain patients. ‘Chronic cancer pain’ ...
Breaking Medicine News(10 mins):